Investigating the role of a specific enzyme in Alzheimer's disease and its effects on brain function.
GLO1/Aβ-mediated mitochondrial and synaptic injury in Alzheimer's disease
This study is looking at how a specific enzyme called Glyoxalase 1 might help protect the brain from damage in Alzheimer's disease, with the hope of finding new ways to improve treatment for people living with this condition.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Columbia University Health Sciences NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10639086 on NIH RePORTER |
What this research studies
This research focuses on understanding how mitochondrial dysfunction and synaptic damage contribute to Alzheimer's disease (AD). It explores the role of Glyoxalase 1 (GLO1), an enzyme that detoxifies harmful metabolites, in the context of amyloid-β accumulation, which is a hallmark of AD. By studying mouse models and human brain samples, the research aims to uncover the mechanisms linking GLO1 function to neuroinflammation and cognitive decline in Alzheimer's patients. The ultimate goal is to identify potential therapeutic strategies that could enhance GLO1 activity to mitigate the effects of AD.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Alzheimer's disease, particularly those experiencing early symptoms.
Not a fit: Patients with other forms of dementia unrelated to Alzheimer's disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that slow down or prevent cognitive decline in Alzheimer's disease.
How similar studies have performed: Previous research has shown promising results in targeting metabolic pathways in Alzheimer's disease, suggesting that this approach could yield significant insights.
Where this research is happening
New York, United States
- Columbia University Health Sciences — New York, United States (Active)
Researchers
- Principal investigator: Yan, Shirley Shidu — Columbia University Health Sciences
- Study coordinator: Yan, Shirley Shidu
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.